Sign in

CIK 0001782223

  • Emerging growth company

Pyxis Oncology, Inc.

Sign in to watch
Ticker
PYXS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831160910
Phone
+1 617-221-9059
Business address
321 HARRISON AVENUE, BOSTON, MA, 02118
  1. 4 Open-market sale President and CEO sold 27,917 shares at an average $2.27 ($63,301)
  2. 4 Grant or award CFO and COO acquired 187,793 shares (grant or award)
  3. 4 Grant or award Chief Accounting Officer acquired 93,896 shares (grant or award)
  4. 4 Grant or award President and CEO acquired 469,483 shares (grant or award)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Grant or award President and CEO acquired 703,379 shares (grant or award)
  8. 4 Grant or award CFO and COO acquired 209,803 shares (grant or award)
  9. 4 Grant or award Chief Medical Officer acquired 209,803 shares (grant or award)
  10. 4 Grant or award Chief Accounting Officer acquired 74,393 shares (grant or award)
  11. 4 Grant or award Director acquired 139,355 shares (grant or award)
  12. 4 Grant or award Director acquired 58,064 shares (grant or award)
  13. 4 Grant or award Director acquired 139,355 shares (grant or award)
  14. 4 Grant or award Director acquired 139,355 shares (grant or award)
  15. 4 Grant or award Director acquired 139,355 shares (grant or award)
  16. 4/A Open-market buy 10% owner bought 1,811,594 shares at $2.76 ($4,999,999)
  17. 4 Open-market buy 10% owner bought 1,811,594 shares at $2.76 ($4,999,999)
  18. 4 Grant or award Chief Executive Officer acquired 95,684 shares (grant or award)
  19. 4 Grant or award Chief Medical Officer acquired 53,931 shares (grant or award)
  20. 4 Grant or award Chief Financial Officer acquired 43,493 shares (grant or award)

Page 4 of 7 · 126 filings